IMPORTANT UPDATE: In an effort to bring you the most pressing and timely scientific updates that were set to be announced at the HFSA Annual Scientific Meeting, Late Breaking Clinical Research sessions were livestreamed on Sunday, September 29 and Monday, September 30 at 9:00 AM ET and available as recorded presentations.
Late Breaking Clinical Research sessions are always-popular sessions during which speakers present the results of new or rapidly evolving research in heart failure. Late Breaking Clinical Research Sessions provide exposure and recognition for major randomized trials and registries that will likely have a significant impact on clinical practice or result in significant advances in the field. Presenters give 8 minute presentations, followed by a 4 minute presentation by a discussant.
Session Details and Recordings
Details and recordings for both Late Breaking Clinical Research sessions are available below. Click the images for more information.
Session Details
Expand All- Efficacy Of Semaglutide In Patients With Obesity And HFpEF According To Frailty Status: A Pooled Analysis From The STEP-HFpEF Program
- Effects Of Semaglutide In Patients With Obesity-related Heart Failure With Preserved Ejection Fraction According To The Exercise Function At Baseline: Insights From The STEP-HFpEF Program
- Efficacy And Safety Of Finerenone In Patients With Heart Failure And Mildly Reduced Or Preserved Ejection Fraction And A Recent Worsening Heart Failure Event: The FINEARTS-HF Trial
- Efficacy And Safety Of Finerenone Across The Ejection Fraction Spectrum In Heart Failure With Mildly Reduced And Preserved Ejection Fraction: The FINEARTS-HF Trial
- Exploratory Biomarker Analyses From HELIOS-B, A Phase 3 Study of Vutrisiran In Patients with Transthyretin Amyloidosis with Cardiomyopathy
- Effects of Vutrisiran on Echocardiographic Cardiac Structure and Function: The HELIOS-B Trial
- Global Clinical Impact Of Aficamten In Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
- Myosin Inhibition In Heart Failure With Preserved Ejection Fraction: Primary Results Of The EMBARK HFpEF Trial
- Impact Of Pharmacological Therapy On Hemocompatibility Following Left Ventricular Assist Device Implantation: An Analysis From The ARIES-HM3 Trial
- Atrial Secondary Mitral Regurgitation Outcomes Following Mitral Transcatheter Edge-to-Edge Repair With The MitraClip System
- A Novel Controlled Metabolic Accelerator For The Treatment Of Obesity-related Heart Failure With Preserved Ejection Fraction: HuMAIN-HFpEF Trial
Rapid Fire Oral Sessions
Expand AllMPORTANT UPDATE: As of September 27, 2024, these sessions have not been rescheduled. The abstracts associated with these sessions will be available in the HFSA ASM 2024 mobile app at the time of the original presentation seen below.
NEW in 2024! Rapid Fire Oral Sessions are fast-paced oral presentations spotlighting key data from late breaking clinical research. Sessions take place Saturday, Sunday and Monday with Q&A and a new topic each day. During each Rapid Fire session, a team of moderators will lead the audience through 7 selected presentations, and introduce each presenter. Each Rapid Fire presentation slot will last 7 minutes. Each presenter will have approximately 5 minutes to present highlights of his or her work, followed by 2 minutes of Q&A from the moderators and attendees. Presenters may prepare three (3) slides to present.
Featuring the Following:
Saturday, September 28 | Rapid Fire 1: Not Just Plug and Play: Devices and Health Technology in Heart Failure | 4:00 PM - 5:00 PM
- Interstitial Decongestion with Device-Based Thoracic Duct Decompression in Acute Decompensated Heart Failure Patients
- Recover-Hf Pilot Study: Synchronized Diaphragmatic Stimulation For HFrEF Therapy
- PROACTIVE HF: 12-Month Results
- Safety And Technical Endpoints And Accurate Volume Assessment Using An Implanted Inferior Vena Cava Sensor
- Electronic Alerts To Improve Heart Failure Therapy Throughout An Integrated Health System: Prompt-HF Inova
- Effect Of Finerenone On Kansas City Cardiomyopathy Questionnaire (KCCQ) Score In Heart Failure With Mildly Reduced And Preserved Ejection Fraction: The FINEARTS-HF Trial
Sunday, September 29 | Rapid Fire 2: Birds of a Feather: Cardio-kidney-metabolism and HFpEF | 5:15 PM - 6:15 PM
- Efficacy And Safety Of Finerenone According To Age In Heart Failure With Mildly Reduced And Preserved Ejection Fraction: The FINEARTS-HF Trial
- The effects of burst steroid therapy on short term decongestion in acute heart failure: the CORTAHF randomized, open-label, pilot trial
- Effects Of Exogenous Ketone Therapy On Exercise Capacity In Heart Failure With Preserved Ejection Fraction: KETO-HFpEF
- Metabolic Responses To Exercise Following Weight Loss Surgery: WTLOSS-EX Trial
- Efficacy Of A Home-based M-health Cardiac Rehabilitation Program Among Older Adults With Heart Failure With Preserved Ejection Fraction: A Pilot Randomized Controlled Trial
- Understanding The Real-World Management Of Patients With Heart Failure At Risk For Hyperkalemia: Initial Results From The CARE-HK In Heart Failure (HF) Registry
- Unsaturated Fatty Acids To Improve Cardiorespiratory Fitness In Obesity-related Heart Failure With Preserved Ejection Fraction: The UFA-Preserved2 Randomized Controlled Cross-over Study
Monday, September 30 | Rapid Fire 3: See One, Do One: Emerging Therapeutic Strategies in Cardiomyopathies and Heart Failure | 10:45 AM - 11:45 AM
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study On The Safety And Efficacy Of Istaroxime For Pre-cardiogenic Shock
- First In Human Gene Therapy For The Cardiomyopathy Of Friedreich Ataxia
- Differences In Self -care Of Heart Failure Index Among Patients With Heart Failure With And Without Symptom Coaching Messages: A Pilot Clinical Trial Study
- Efficacy Of Single Dose Furoscix Vs. Home Dose Furosemide In Patients Recently Hospitalized For Heart Failure Across Diuretic Resistance Strata: A Pilot Randomized Controlled Trial
- AuXillary OUTpatient Management Of VAD BLEEDing: The AXOUT VAD BLEED Pilot Study
- Pulmonary Artery Pressures In Relation To Serial Cardiovascular Blood Biomarkers In Chronic Heart Failure Patients
- American Registry Of Ambulatory Or Acute Decompensated Heart Failure (AMERICCAASS): Current Results
Embargo Policy and Submission Information
Expand AllAbstracts accepted are embargoed for release until the time of presentation at the Heart Failure Society of America's Annual Scientific Meeting.
The standard is that any company can announce at any time the following:
- Announcement that trial/research is completed
- That results will be presented at so and so date in such and such a meeting
- What did the trial/research assess - basic design, questions, study population, interventions, etc.
Clinical research abstracts accepted for presentation will be:
- Either presented during the Late Breaking Clinical Research session
- Or presented during a Rapid Fire Spotlight Oral session
- Accepted Late Breaking Clinical Research abstracts from the plenary session will be published in an issue of the Journal of Cardiac Failure after the Annual Scientific Meeting. Authors will have the ability to update the submitted abstract prior to publication. JCF encourages all accepted Late Breaking Clinical Research to submit full papers for further consideration
All late breaking data is embargoed until the day of Late Breaking Clinical Research session.
If an accepted late breaking clinical research abstract was submitted and accepted for general abstract/poster presentation at the HFSA Annual Scientific Meeting, it needs to be withdrawn by August 2, 2024.